ALVAX | VIVIX | ALVAX / VIVIX | |
Total Expense Ratio | 1.01 | 0.04 | 2,525% |
Annual Report Gross Expense Ratio | 1.01 | 0.04 | 2,525% |
Fund Existence | 15 years | 27 years | - |
Gain YTD | 9.103 | 7.866 | 116% |
Front Load | 6% | N/A | - |
Min. Initial Investment | 2500 | 5000000 | 0% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 3.41B | 203B | 2% |
Annual Yield % from dividends | 1.69 | 2.11 | 80% |
Returns for 1 year | -2.00 | 7.74 | -26% |
Returns for 3 years | 12.89 | 36.61 | 35% |
Returns for 5 years | 18.63 | 70.16 | 27% |
Returns for 10 years | 5.28 | 131.61 | 4% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
LYFAX | 13.30 | 0.22 | +1.68% |
AlphaCentric Life Sciences & Hlthcare A | |||
VGPMX | 17.01 | 0.21 | +1.25% |
Vanguard Global Capital Cycles Investor | |||
JHUKX | 37.15 | 0.40 | +1.09% |
JPMorgan Emerging Markets Equity R4 | |||
CRCRX | 9.78 | 0.08 | +0.82% |
NYLI CBRE Real Estate Class C | |||
CMIDX | 22.44 | 0.16 | +0.72% |
Congress Mid Cap Growth Retail |